NASDAQ: IMVT

Immunovant (IMVT) Stock Analysis & Forecast

Nov 13 close

$34.18−0.87 (−2.5%)

Gekko Brief

AI summaryNov 9 close

Immunovant reported fiscal second-quarter results on 9 November, topping estimates with an EPS of ($0.47) against a projected ($0.74) loss. The quarter's focus was IMVT-1402, which met its primary endpoint in a trial for difficult-to-treat rheumatoid arthritis, with FDA discussions planned later this year for its registrational program. Roivant's call also disclosed $31 million in net revenue from the initial launch of LISRAYA, alongside a Form 8K filing tied to the announcement and coverage noting a prior setback in the cutaneous lupus erythematosus program ahead of this report.

Shares closed at $35.15, up 15.1% on the day, trading above both the 50-day average of $32.98 and the 200-day average of $32.17, with the 50-day above the 200-day. The GekkoIndex reading sits at 48.3, placing it in the Neutral zone, and the stock trades essentially in line with Gekko Fair Value of $35.19, a gap of -0.1%.

No confirmed earnings date is on the calendar for the next 20 trading days, and no insider, Congress, or unusual options activity appears in the current window. Seasonality over the past 5 years shows an average 20-day return of 1.3% from this point, rising in 2 of those years. Analyst coverage currently shows 6 buy and 3 hold ratings among 9 firms, with a consensus target of $48.88.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Immunovant price vs fair value

$35.29$34.18Nov ’25May ’26Nov ’26
Close $34.18200-day averageGekko Fair Value $35.29

Immunovant quick facts

Market cap
$7.07B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$2.56
Revenue, TTM
$0
Profit margin
0%
Dividend yield
—
Beta
0.94
Volume
864,692 avg 1.44M
1-year return
+45.8%
Typical daily move
±4.9%
Typical 20-day move
±10.1%
50-day average
$32.64
200-day average
$32.35
Next earnings
Feb 5 before open
Shares outstanding
206.9M
52-week range
$21.86$45.42

Immunovant swing-trade checklist

Immunovant scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive2 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $34.18 is above the 50-day ($32.64) and 200-day ($32.35) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    51.9, Neutral

    Reading 51.9 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    3.1% below

    Price is within 5% of Gekko Fair Value (3.1% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 82 days

    Next report Feb 5, 2027, 82 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +7.2% on average

    From this point in the calendar, the next 20 trading days averaged +7.2% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Immunovant stock chart and price history

Immunovant closed at $34.18 on Nov 13, 2026, +45.8% over the past year, inside a 52-week range of $21.86 to $45.42.

Close50-day average200-day averageVolume
Immunovant share price, past year, with 50-day and 200-day moving averages and volume$20$30$40DecJan 2026FebMarAprMayJunJulAugSepOctNov34.18

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+24.2%
3 months
−21.8%
6 months
+24.3%
1 year
+45.8%
The full IMVT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IMVT in Gekko

Follow Immunovant through every session

Put IMVT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track IMVT in GekkoFree for 7 days. No credit card required.

About Immunovant

Immunovant develops monoclonal antibody treatments aimed at autoimmune diseases and remains in the clinical testing stage of drug development. Its lead candidate, batoclimab, is a fully human antibody designed to block the neonatal fragment crystallizable receptor, known as FcRn, which plays a role in a number of autoimmune conditions. The company is best recognized for this program, which spans several disease areas rather than a single condition.

Batoclimab is being studied in Phase IIa trials for myasthenia gravis and thyroid eye disease, and has entered Phase II testing for warm autoimmune hemolytic anemia. Immunovant operates as a subsidiary of Roivant Sciences Ltd, situating its research within that broader corporate structure rather than as a fully independent entity.

The company was founded in 2018 and is headquartered in New York, New York. Its shares are listed on the NASDAQ under the ticker IMVT.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
immunovant.com

Immunovant GekkoIndex: the smart money zone

Immunovant’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.9, in the Neutral zone, down 6.8 points over five sessions.

010051.9Neutral

Down 6.8 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying76−1.0%−1.7%−4.3%−10.7%
Accumulation247−0.8%−1.7%−2.9%+0.4%
Neutral (current zone)350+1.0%+1.9%+3.2%+5.6%
Distribution28−2.5%−4.9%−4.0%−3.3%
Selling1Too few readings yet

Average IMVT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the IMVT price, zone by zone.Track IMVT in Gekko

Is Immunovant stock overvalued? Gekko Fair Value

Immunovant trades 3.1% below Gekko Fair Value of $35.29, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Immunovant shares are worth, recalculated every trading day.

$35.29

Gekko Fair Value, Nov 14, 2026

3.1% below fair value · About fair value

At the end of Aug 2026 the price was 11.0% below the estimate.

Gekko Fair ValueShare price, month end
$35$34Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open IMVT in Gekko

Immunovant insider and Congress trading

No open-market insider purchases were filed for Immunovant, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for IMVT in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every IMVT insider filing, plotted on the chart in Gekko.Open IMVT in Gekko

Congress trades last 90 days

No trades in IMVT were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for IMVT, plotted on the chart in Gekko.Open IMVT in Gekko

Hedge funds and billionaires quarter ended Mar 31

1of the funds Gekko tracks holds IMVT.

0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Immunovant earnings: next date and track record

Immunovant reports on Feb 5, 2027, before the open (82 days away), and beat the EPS estimate in 3 of its last 8 reports.

3 of 8reports beat the EPS estimate
±8.3%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

−2.5%Nov ’24−9.3%Feb ’25+5.3%May ’25−1.6%Aug ’25−2.0%Nov ’25+14.3%Feb ’26+29.8%May ’26+1.7%Aug ’26

Last earnings call, Aug 6, 2026 AI summary

What they said
Roivant's Q1 2026 earnings call described a quiet quarter operationally but with meaningful programmatic progress and upcoming catalysts. Management highlighted a pending brexpiprazole launch expected by the end of September (PDUFA this quarter), Phase III enrollment started for cutaneous sarcoidosis, continued enrollment for LPP and other brexpiprazole indications, initial settlement payment from Moderna and ongoing international proceedings against Pfizer/BioNTech, and multiple program readouts and regulatory interactions expected in the second half of the year. Management emphasized execution on multiple programs (brepocitinib in dermatomyositis and NIU, mosely/Mosley for PH-ILD, 1402 for difficult-to-treat RA and Graves disease, 402 for MG/CIDP, CLE proof-of-concept), expressed confidence in market opportunity and physician receptivity, and flagged key programmatic risks such as placebo variability in immunology trials and translational risk from PAH to PH-ILD. The tone was measured and optimistic: management repeatedly emphasized progress, patient need, and preparedness for potential launches, while acknowledging uncertainties (placebo response, trial translation, reimbursement dynamics).
Guidance
Brexpiprazole expected to launch by the end of September (PDUFA this quarter). Management plans to provide more launch metrics and cadence around approvals as events occur; they did not provide formal quantitative financial guidance for the quarter. They expect multiple program readouts and regulatory interactions in the second half of 2026 and indicated intent to file sNDAs/registrations promptly if pivotal data are positive.
Risks flagged
Placebo response variability in immunology trials (could impact Phase III success); translational risk of inhaled vasodilators from PAH to PH-ILD (uncertainty whether PVR reductions will translate); JAK class safety concerns and black box warnings (physician reception and label expectations); reimbursement and formulary timing risks impacting early launch uptake; geographic and baseline variability across Phase III trials (could affect outcomes); regulatory timing and requirement uncertainty (may affect filing cadence).
ReportedEPSSurpriseRevenueSurpriseMove
Aug 6, 2026−$0.75
est −$0.66
−13.6%$7.10M
est $7.10M
0.0%+1.7%
May 20, 2026−$0.67
est −$0.63
−6.3%——+29.8%
Feb 6, 2026−$0.54
est −$0.69
+21.7%—
est $6.00M
—+14.3%
Nov 10, 2025−$0.73
est −$0.72
−1.4%——−2.0%
Aug 11, 2025−$0.60
est −$0.69
+13.0%——−1.6%
May 29, 2025−$0.64
est −$0.71
+10.3%——+5.3%
Feb 6, 2025−$0.76
est −$0.75
−1.3%——−9.3%
Nov 7, 2024−$0.74
est −$0.61
−21.3%——−2.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Immunovant stock forecast and analyst price targets

Analysts’ average 12-month price target for Immunovant is $48.50, +41.9% from the last close, from 9 firms rating the stock in the last 90 days.

$48.50consensus 12-month target, +41.9% from the last close
Low $33High $66
Buy6
Hold3
Sell0

Each firm’s latest rating in the last 90 days: 9 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 12J.P. MorganBuy, maintained$49+43.4%
Nov 10Truist FinancialHold, maintained$33−3.5%
Nov 10H.C. WainwrightBuy, reiterated$41+20.0%
Nov 10Wells FargoBuy, reiterated$47+37.5%
Nov 9Bank of America SecuritiesBuy, reiterated$46+34.6%
+3.2%average 20-day move after past Neutral readings
+7.2%average move over the next 20 trading days in the last 5 years
±4.9%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Immunovant seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Immunovant averaged +7.2% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−10.4%2021+16.8%2022+24.6%2023−6.3%2024+9.5%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−4.0%1 of 5
Next 10 trading days−0.1%2 of 5
Next 15 trading days+3.8%2 of 5
Next 20 trading days+7.2%3 of 5
Next 30 trading days+9.0%3 of 5

For scale, IMVT’s typical 20-trading-day move in either direction is about 10.1%.

Immunovant market cap and key statistics

Immunovant’s market cap is $7.07B and revenue of $0 over the last twelve months.

Valuation

Market cap
$7.07B
EPS, TTM
−$2.56
Gekko Fair Value
$35.29

Trading

Volume
864,692
Avg volume, 20 days
1.44M
52-week high
$45.42
52-week low
$21.86
Shares outstanding
206.9M

Financials

Revenue, TTM
$0
Profit margin
0%
Return on equity
-86.5%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
0.94
Typical daily move
±4.9%
Typical 20-day move
±10.1%

Immunovant stock news this week

Coverage of Immunovant this week reads positive: 5 positive, 2 neutral and 2 negative headlines.

News sentiment positive

Immunovant peers

Immunovant’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Immunovant stock FAQ

What is Immunovant’s market cap?

Immunovant’s market cap is $7.07B at the Nov 13, 2026 close of $34.18, with 206.9M shares outstanding.

What is the Immunovant stock forecast?

The consensus analyst 12-month price target for Immunovant is $48.50, +41.9% from the last close. Of the 9 firms that rated the stock in the last 90 days, 6 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Immunovant stock overvalued or undervalued?

On Gekko’s estimate Immunovant is about fair value: the Nov 13, 2026 close of $34.18 is 3.1% below Gekko Fair Value of $35.29. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Immunovant report earnings next?

Immunovant is expected to report on Feb 5, 2027, before the market opens (82 days away). Analysts expect earnings of −$0.68 per share. Immunovant beat the earnings estimate in 3 of its last 8 reports, moving 8.3% on average across the report.

What is Immunovant’s 52-week high and low?

Immunovant’s 52-week high is $45.42 and its 52-week low is $21.86; it closed at $34.18 on Nov 13, 2026, +45.8% over the past year. Over the last five years the shares peaked at $45.58 on Jan 9, 2024.

Is Immunovant stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Immunovant the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.